



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/165,546	10/02/1998	KNUTH ALEXANDER	LUD5466.4-JE	8012

24972 7590 12/14/2001

FULBRIGHT & JAWORSKI, LLP  
666 FIFTH AVE  
NEW YORK, NY 10103-3198

EXAMINER

DECLoux, AMY M

ART UNIT PAPER NUMBER

1644

DATE MAILED: 12/14/2001

24

Please find below and/or attached an Office communication concerning this application or proceeding.

FILED - 12

81, SEARCHED BY [illegible] ON [illegible]  
[illegible] [illegible] [illegible]  
[illegible] [illegible] [illegible]  
[illegible] [illegible] [illegible]  
[illegible] [illegible] [illegible]

## Interview Summary

Application No.

09/165,546

Applicant(s)

Alexander et al.

Examiner

D Cloux, Amy

Group Art Unit

1644



All participants (applicant, applicant's representative, PTO personnel):

(1) DeCloux, Amy(3) Skipper, Thomas(2) Hanson, Norman

(4) \_\_\_\_\_

Date of Interview Dec 11, 2001Type: a) ☒ Telephonic b) ☐ Video Conferencec) ☐ Personal (copy is given to 1) ☐ applicant 2) ☒ applicant's representative]Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No. If yes, brief description:Claim(s) discussed: 74

Identification of prior art discussed:

NoneAgreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☒ No.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments:

Applicant contends that the outstanding 112 first written description rejection should be withdrawn on the grounds that the disclosure of six peptides of 18 residues each, which bind to HLA-DR53, wherein three of said peptides stimulate recognition and proliferation of CD4+ cells which are specific for complexes of said peptide and HLA-DR53 molecules, is adequate written description of the base claim 74's recitation of a peptide comprising 18-25 amino acids, comprising at least one HLA-DR53 binding motif wherein the first amino acid is Y, F, W or L and the 4th is A or S. Applicant contends that the disclosure of said six peptides in combination with Futaki et al's teaching of said HLA-DR53 binding motif, constitutes adequate written description of the instant claims. Applicant also contends that their invention is distinct from the teachings of Futaki et al because the instant claims recite peptides of 18-25 amino acids, while the peptides taught by Futaki range in length from 11-17 amino acids. The examiner agreed to reconsider upon applicant's response to the outstanding office action.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

i) ☐ It is not necessary for applicant to provide a separate record of the substance of the interview (if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

*Amy De Cloux 12/12/01*